<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715960</url>
  </required_header>
  <id_info>
    <org_study_id>2016 AW/CSU/PS</org_study_id>
    <nct_id>NCT02715960</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules</brief_title>
  <official_title>Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In an early clinical research, 138 patients completed the treatment of Psoriasis Vulgaris by&#xD;
      Acitretin Capsules in 8 weeks, the results indicate 75 cases effectively (54.3%), 50 cases&#xD;
      invalid(36.2%), 13 cases serious(9.4%). To investigate the influence of genetic factors on&#xD;
      the curative effect and find the relationships between genetic variants and the response of&#xD;
      Acitretin Capsules to treatment of Psoriasis Vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators analyzed the various levels of genetic factors, including: 1.To analysis the&#xD;
      key gene variants which associated with ADME affect the efficacy of Acitretin Capsules;&#xD;
      2.Direct full genetic sequencing of MHC genes, to explore the genetic variations of efficacy&#xD;
      and side effects; 3. Direct sequencing of all exons in the gene in the patients of the&#xD;
      response of serious and effectively, to explores the rare genetic variation may cause&#xD;
      deterioration of treatment by Acitretin Capsules.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control rate</measure>
    <time_frame>8 weeks after the first treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin Capsules</intervention_name>
    <description>During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.</description>
    <arm_group_label>single-arm</arm_group_label>
    <other_name>Tretinoin, Vitamine A Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed according to Classification criteria for Psoriasis vulgaris&#xD;
&#xD;
          2. Patients aged 18 to 70 years (to the date of screening)&#xD;
&#xD;
          3. PASI grade â‰¥7point&#xD;
&#xD;
          4. Not treatment in the Topical corticosteroids, Immunosuppression, Biologicals agents or&#xD;
             Tretinoin cream, Phototherapy nearly one months before enrolled.&#xD;
&#xD;
          5. Total bilirubin &lt; 1.5 x ULN, AST(SGOT)/ALT(SGPT) &lt;2.5 x ULN if not liver metastases&lt;5&#xD;
             x ULN if known liver metastases, Creatinine clearance &lt;1.5 x ULN&#xD;
&#xD;
          6. Understanding the whole process of the study, voluntary participation and signed the&#xD;
             informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women, ready to pregnant or lactating women&#xD;
&#xD;
          2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions&#xD;
             and the history&#xD;
&#xD;
          3. Patients is liver function abnormal persons (ALT above the center laboratory normal&#xD;
             limit) or hepatitis b patient grain carriers&#xD;
&#xD;
          4. Patients with chronic diarrhea, or peptic ulcer nearly 1 year&#xD;
&#xD;
          5. Patients suffering from malignant tumor&#xD;
&#xD;
          6. Patients suffering from acute and chronic infectious diseases&#xD;
&#xD;
          7. Mental disorders, history of alcohol abuse, drug or other substance abuse&#xD;
&#xD;
          8. Other cases which researchers believe that can not enroll&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yijing He, PhD,MD</last_name>
    <phone>+86-1587481262</phone>
    <email>yijinghe@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yijing He, MD, PhD</last_name>
      <phone>+86-1587481262</phone>
      <email>yijinghe@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Yijing He</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>data not entered</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

